Bluejay CEO buys 12,500 shares at $2

Bluejay Diagnostics, Inc. director and President/CEO Indranil Dey bought additional company stock.

Rhea-AI Filing Summary

Bluejay Diagnostics, Inc. director and President/CEO Indranil Dey bought additional company stock. On March 14, 2026, he purchased 12,500 shares of common stock from the company in a private placement at $2.00 per share, bringing his direct holdings to 12,522 shares. He also indirectly owns 127 shares held by Lana Management & Business Research International, LLC, over which he has voting and dispositive power.

Insider Trade Summary

Net Buyer: 12,500 shares

Net Buy 2 txns

Insider Dey Indranil

Role President and CEO

Bought 12,500 shs ($25K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	12,500	$2.00	$25K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 12,522 shares (Direct); Common Stock — 127 shares (Indirect, Held by Lana Management & Business Research International, LLC)

Footnotes (2)

1. F1. On March 14, 2026, Mr. Dey purchased 12,500 shares of the issuer's common stock from the issuer in a private placement at a price of $2.00 per share.
2. F2. Lana Management & Business Research International, LLC is an entity owned by Mr. Indranil Dey and Ms. Svetlana Dey. Mr. Dey has voting and dispositive power over the shares held by such entity.

Key Figures

Shares purchased: 12,500 shares Purchase price: $2.00 per share Direct holdings after transaction: 12,522 shares +1 more

4 metrics

Shares purchased 12,500 shares Common Stock bought on March 14, 2026

Purchase price $2.00 per share Private placement from issuer

Direct holdings after transaction 12,522 shares Common Stock directly owned by Indranil Dey

Indirect holdings 127 shares Held by Lana Management & Business Research International, LLC

Key Terms

private placement, voting and dispositive power, Common Stock, open-market purchase

4 terms

private placement financial

"purchased 12,500 shares of the issuer's common stock from the issuer in a private placement at a price of $2.00 per share"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

voting and dispositive power financial

"Mr. Dey has voting and dispositive power over the shares held by such entity"

Common Stock financial

"On March 14, 2026, Mr. Dey purchased 12,500 shares of the issuer's common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open-market purchase financial

"transaction_action": "open-market purchase", "transaction_code_description": "Purchase in open market or private transaction""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Bluejay Diagnostics (BJDX) report for Indranil Dey?

Bluejay Diagnostics reported that President and CEO Indranil Dey bought 12,500 shares of common stock on March 14, 2026. The purchase was part of a private placement directly from the company at $2.00 per share, increasing his direct ownership stake.

At what price did Indranil Dey buy Bluejay Diagnostics (BJDX) shares?

Indranil Dey bought Bluejay Diagnostics common stock at $2.00 per share. The Form 4 shows a 12,500-share purchase in a private placement from the issuer at this price, representing a direct cash investment into the company’s equity.

How many Bluejay Diagnostics (BJDX) shares does Indranil Dey own after this transaction?

After the transaction, Indranil Dey holds 12,522 shares directly and 127 shares indirectly. The indirect shares are owned through Lana Management & Business Research International, LLC, giving him both voting and dispositive power over that additional position.

Was the Bluejay Diagnostics (BJDX) insider purchase an open-market trade?

No, the filing specifies that the 12,500-share purchase was a private placement from the issuer. Although coded as a purchase transaction, the footnote clarifies it occurred directly with the company rather than through open-market trading.

Who holds the indirect Bluejay Diagnostics (BJDX) shares related to Indranil Dey?

The indirect shares are held by Lana Management & Business Research International, LLC. This entity is owned by Indranil Dey and Svetlana Dey, and the filing notes that Mr. Dey has voting and dispositive power over the shares held by the LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 05:20 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dey Indranil

(Last) (First) (Middle)

C/O BLUEJAY DIAGNOSTICS, INC.

360 MASSACHUSETTS AVENUE, SUITE 203

(Street)

ACTON MASSACHUSETTS 01720

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Bluejay Diagnostics, Inc. [ BJDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/14/2026		P		12,500(1)	A	$2	12,522	D
Common Stock								127	I	Held by Lana Management & Business Research International, LLC(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On March 14, 2026, Mr. Dey purchased 12,500 shares of the issuer's common stock from the issuer in a private placement at a price of $2.00 per share.

2. Lana Management & Business Research International, LLC is an entity owned by Mr. Indranil Dey and Ms. Svetlana Dey. Mr. Dey has voting and dispositive power over the shares held by such entity.

	/s/ Indranil Dey	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)